SEENU M. HARIPRASAD, MD
COURSE DIRECTOR
Professor, Department of Ophthalmology and Visual Science; Chief, Vitreoretinal Service, University of Chicago

THOMAS A. ALBINI, MD
Associate Professor of Clinical Ophthalmology, Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine

KIMBERLY DRENSER, MD
Vitreoretinal Surgeon, Associated Retinal Consultants; Clinical Professor, William Beaumont Oakland University College of Medicine; Director of Ophthalmology Research - Retina, William Beaumont Hospital

SHARON FEKRAT, MD
Associate Professor in the Departments of Surgery and Ophthalmology, Duke University Medical Center; Associate Chief of Staff for Surgical Services, Durham VA Medical Center, Durham, NC

CARL D. REGILLO, MD
Director of the Retina Service and Professor of Ophthalmology, Wills Eye Hospital, Thomas Jefferson University, Philadelphia

ELIAS REICHEL, MD
Vice Chair for Research and Education, Department of Ophthalmology, Director of Vitreoretinal Diseases and Surgery Service, and Director of Medical Retina Fellowships, New England Eye Center, Tufts University School of Medicine

Intended Audience

Retina specialists, including Residents and Fellows

Learning Objectives

Upon completion of this activity, participants should be able to:

• ❒ Evaluate and discuss safety and efficacy based on clinical trials data for intravitreal VEGF inhibitors in the treatment of DME.
• ❒ Evaluate and discuss safety and efficacy from data generated by the DRCR Protocol T trial, the first and only prospective comparative study looking at treatments for DME in a head-to-head comparison.
• ❒ Evaluate and discuss safety and efficacy data based on pivotal clinical trials of intravitreal corticosteroids in the treatment of DME.
• ❒ Discuss the role of dexamethasone in vitrectomized eyes with DME and its use in the treatment of suboptimal responders to anti-VEGF treatment.
• ❒ Understand current issues in the treatment of DME, such as the use of combination therapies.

Statement of Need

Diabetic patients with macular edema report a vision-related quality of life that is worse than diabetic patients with cataract or glaucoma, but treatment can lead to improvement in most of these domains. Combination therapies that might reduce the burden of chronic treatment are under investigation, but until these become proven options, there is a need to determine treatment and management strategies that lower the burden of illness, lower the burden of treatment, and enhance overall quality of life for patients and their caregivers.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Dannemiller and PentaVision. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

Dannemiller designates this journal supplement for a maximum of 1.0 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

Participants should first read the objectives and other introductory CME information; then proceed to the educational activity online at dannemiller.com/test/1034 . To receive credit for this activity, participants must complete the online post-test with a passing score of 80% and then complete the evaluation. Credit is provided through Feb. 28, 2017. No credit will be given after this date. There is no fee to participate in this activity.

In the event you have questions about this activity or are unable to retrieve the certificate, please e-mail cme@dannemiller.com and a certificate will be emailed within 2 weeks.

System Requirements

• ❒ Computer or smartphone with Internet access
• ❒ Web browser (IE 7.0+ or Webkit/Mozilla Compatible) with JavaScript enabled

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education (ACCME), Dannemiller requires that any person who is in a position to control the content of a CME/CE activity must disclose all financial relationships with a commercial interest.

The following faculty reported no relevant financial disclosures:

• ❒ Sharon Fekrat, MD

The following faculty members have disclosures to be made:

• ❒ Thomas A. Albini, MD, has reported consulting agreements with Allergan, Bausch + Lomb, and Santen.
• ❒ Kimberly Drenser, MD, PhD, has reported speaker bureau and consultant agreements with Allergan and Thrombogenics; consultant agreements with Spark Therapeutics and Synergetics; and a stockholder relationship with FocusROP and Retinal Solutions.
• ❒ Seenu M. Hariprasad, MD, has reported consultant and speaker bureau agreements for Alcon, Allergan, Bayer, Clearside Biomedical, Genentech, Janssen, Ocular Therapeutix, OD-OS, Optos, Regeneron, Spark, and Takeda.
• ❒ Carl D. Regillo, MD, has reported consulting and investigator agreements with Alcon, Allergan, Genentech, and Regeneron.
• ❒ Elias Reichel, MD, has reported speaker bureau agreements with Regeneron.

Alex Yuan, MD, content reviewer; Myra Garcia, Dannemiller project manager; Virgina Pickles, writer; and Angela Jackson, Rachel Dance, and Alicia Hoglund, PentaVision Special Projects; have no financial relationships with commercial interests.

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a member of the Dannemiller Clinical Content Review Committee. The resulting certified activity was found to provide educational content that is current, evidence based, and commercially balanced.

Off-label Statement

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller, PentaVision LLC, Allergan, or Regeneron. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject.